Omalizumab in chronic spontaneous urticaria


  • Ramesh A. Department of Dermatology, Madras Medical College, Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu
  • Sampath V. Department of Dermatology, Madras Medical College, Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu
  • Dhanalakshmi U. R. Department of Dermatology, Madras Medical College, Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu
  • Vinitha Kumari G. Department of Dermatology, Madras Medical College, Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu



Chronic spontaneous urticaria, Urticaria activity score, Omalizumab


Background: Chronic spontaneous urticaria is a common skin disorder affecting 0.5 to 1% of people in the general population. There are a variety of treatment options available without much successful outcome. Omalizumab is a novel treatment option which can be used in the treatment of chronic spontaneous urticaria. The aim of our study is to assess the efficacy of omalizumab in chronic spontaneous urticaria.

Methods: A retrospective analysis of data of 10 patients with chronic spontaneous urticaria who were treated with three doses of omalizumab in our institution. Doses were given at monthly intervals for 3 months and they were followed for another 6 months. Response was assessed using urticaria activity score.

Results: 70% of patients had well controlled urticaria with 3 doses of omalizumab by the end of 9 months.

Conclusions:Omalizumab is a safe and effective treatment option in the management of chronic spontaneous urticaria. 



Maurer M, Weller K, Bindslev- Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317-30.

Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14:214−20.

Godse KV, Zawar V, Krupashankar DS, Girdhar M, Kandhari S, Dhar S, et al. Consensus statement on the management of urticarial. IndianJ Dermatol. 2011;56(5):485–9.

Zuberbrier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. THE EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria, the 2013 revision and update. Allergy. 2014;69(7):868-87.

Beltrani VS. An overview of chronic urticaria. Clin Rev Allergy Immunol. 2002;23(2):147–69.

Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35-9

Silvares MR, Fortes MR, Miot HA. Quality of life in chronic urticaria: a survey at a public university outpatient clinic, Botucatu (Brazil). Rev Assoc Med Bras. 2011;57(5):577-82.

Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark At, et al. BSACI guidelines for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2007;37(5):631-50.

Schocket AL. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc. 2006;27(2):90-5.

Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777-87.

Altrichter S, Peter HJ, Pisarevskaja D,Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase- a novel pathomechanism of chronic spontaneous urticarial. PLoS One. 2011;6(4)e14794.

Staubach P, Vonend A, burow G, Metz M, magerl M, Maurer M. patients with chronic urticaria exhibit increased rates of sensitization to candida albicans, but not to common moulds. Mycoses. 2009;52(4):334-8.

Metz M, Maurer M. omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406-11.

Neema S, Chatterjee M. Omalizumab for the management of refractory urticaria: Experience of a tertiary care centre in Eastern India. Indian J Dermatol. 2018;63:66-9.

Tidman MJ, Smith CH. Principles of systemic therapy. Rook’s Textbook of Dermatology. 9th ed. John Wiley& Sons; 2016: 34

Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol. 2010;125:889-95.

Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol. 2004;114:527-30.

Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou T-T, Ying S, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol. 2005;116:558-64.

Subramaniyan R, Chopra A. Treatment of chronic spontaneous urticaria with single dose of omalizumab: A study of four cases. Indian J Dermatol. 2016;61:467.

Uysal P, Eler E, Mortz CG, Bindsley-jensen C. Analgorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized. J Allergy Clin Immunol. 2014;133:914-5.






Original Research Articles